Drug Delivery Business

Satsuma launches Phase 3 trial for acute migraine combination product

By

satsuma-pharmaceuticalsSatsuma Pharmaceuticals (NSDQ:STSA) has announced that it has enrolled the first patient in its SUMMIT Phase 3 efficacy trial of STS101, a drug-device product that is a potential acute treatment of migraine.

STS101 is a nasal powder containing dihydroergotamine (DHE), an analgesic already available to treat migraines and cluster headaches. In fact, migraine patients have used DHE as an acute migraine treatment since 1946. But approved DHE products are “inconvenient or have an inconsistent response,” according to a paper published in Neurology. “Newer development-stage products may provide enhanced [pharmacokinetics], improved clinical efficacy, and more patient-friendly administration,” the article continued.

Get the full story from our sister site, Drug Discovery & Development.

IN CASE YOU MISSED IT

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].